Prevalence, risk factors and evolution of diabetes mellitus after treatment in primary aldosteronism. Results from the SPAIN-ALDO registry.

Autor: Araujo-Castro M; Endocrinology and Nutrition Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. marta.araujo@salud.madrid.org.; Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Colmenar Viejo Street Km 9, 28034, Madrid, Spain. marta.araujo@salud.madrid.org.; University of Alcalá, Madrid, Spain. marta.araujo@salud.madrid.org., Paja Fano M; Endocrinology and Nutrition Department, OSI Bilbao-Basurto, Hospital Universitario de Basurto, Bilbao, Spain.; Medicine Department, Basque Country University, Bilbao, Spain., Pla Peris B; Endocrinology and Nutrition Department, Hospital Universitario de Castellón, Castellón, Spain., González Boillos M; Endocrinology and Nutrition Department, Hospital Universitario de Castellón, Castellón, Spain., Pascual-Corrales E; Endocrinology and Nutrition Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.; Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Colmenar Viejo Street Km 9, 28034, Madrid, Spain., García Cano AM; Biochemistry Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Parra Ramírez P; Endocrinology and Nutrition Department, Hospital Universitario La Paz Madrid, Madrid, Spain., Martín Rojas-Marcos P; Endocrinology and Nutrition Department, Hospital Universitario La Paz Madrid, Madrid, Spain., Ruiz-Sanchez JG; Endocrinology and Nutrition Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain., Vicente Delgado A; Endocrinology and Nutrition Department, Hospital Universitario de Toledo, Toledo, Spain., Gómez Hoyos E; Endocrinology and Nutrition Department, Hospital Universitario de Valladolid, Valladolid, Spain., Ferreira R; Endocrinology and Nutrition Department, Hospital Universitario Rey Juan Carlos, Madrid, Spain., García Sanz I; General and Digestive Surgery Department, Hospital Universitario de La Princesa, Madrid, Spain., Recasens Sala M; Endocrinology and Nutrition Department, Institut Català de La Salut Girona, Girona, Spain., Barahona San Millan R; Endocrinology and Nutrition Department, Institut Català de La Salut Girona, Girona, Spain., Picón César MJ; Endocrinology and Nutrition Department, Hospital Universitario Virgen de La Victoria de Málaga, IBIMA, Málaga, Spain.; CIBEROBN, Madrid, Spain., Díaz Guardiola P; Endocrinology and Nutrition Department, Hospital Universitario Infanta Sofía, Madrid, Spain., Perdomo CM; Endocrinology and Nutrition Department, Clínica Universidad de Navarra, Pamplona, Spain., Manjón Miguélez L; Endocrinology and Nutrition Department, Hospital Universitario Central de Asturias, Oviedo, Spain.; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain., García Centeno R; Endocrinology and Nutrition Department, Hospital Universitario Gregorio Marañón, Madrid, Spain., Percovich JC; Endocrinology and Nutrition Department, Hospital Universitario Gregorio Marañón, Madrid, Spain., Rebollo Román Á; Endocrinology and Nutrition Department, Hospital Reina Sofía, Córdoba, Spain., Gracia Gimeno P; Endocrinology and Nutrition Department, Hospital Rollo Villanova, Saragossa, Spain., Robles Lázaro C; Endocrinology and Nutrition Department, Complejo Universitario de Salamanca, Salamanca, Spain., Morales-Ruiz M; Biochemistry and Molecular Genetics Department-CDB, CIBERehd, Hospital Clinic, IDIBAPS, Barcelona, Spain., Calatayud Gutiérrez M; Endocrinology and Nutrition Department, Hospital Doce de Octubre, Madrid, Spain., Furio Collao SA; Endocrinology and Nutrition Department, Hospital Doce de Octubre, Madrid, Spain., Meneses D; Endocrinology and Nutrition Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain., Sampedro Nuñez MA; Endocrinology and Nutrition Department, Hospital Universitario La Princesa Madrid, Madrid, Spain., Escudero Quesada V; Nephrology Department, Hospital Universitario Doctor Peser, Valencia, Spain., Mena Ribas E; Endocrinology and Nutrition Department, Hospital Universitario Son Espases, Palma, Islas Baleares, Spain., Sanmartín Sánchez A; Endocrinology and Nutrition Department, Hospital Universitario Son Espases, Palma, Islas Baleares, Spain., Gonzalvo Diaz C; Endocrinology and Nutrition Department, Hospital Universitario De Albacete, Albacete, Spain., Lamas C; Endocrinology and Nutrition Department, Hospital Universitario De Albacete, Albacete, Spain., Guerrero-Vázquez R; Endocrinology and Nutrition Department, Hospital Virgen de La Macarena, Seville, Spain., Del Castillo Tous M; Endocrinology and Nutrition Department, Hospital Virgen de La Macarena, Seville, Spain., Serrano Gotarredona J; Endocrinology and Nutrition Department, Hospital General Universitario de Alicante, Alicante, Spain., Michalopoulou Alevras T; Endocrinology and Nutrition Department, Hospital Joan XXIII, Tarragona, Spain., Moya Mateo EM; Internal Medicine, Hospital Infanta Leonor de Vallecas, Madrid, Spain., Hanzu FA; Endocrinology and Nutrition Department, Hospital Clinic, IDIPAS, Barcelona, Spain.
Jazyk: angličtina
Zdroj: Journal of endocrinological investigation [J Endocrinol Invest] 2023 Nov; Vol. 46 (11), pp. 2343-2352. Date of Electronic Publication: 2023 Apr 10.
DOI: 10.1007/s40618-023-02090-8
Abstrakt: Purpose: To evaluate the prevalence, risk factors and evolution of diabetes mellitus (DM) after targeted treatment in patients with primary aldosteronism (PA).
Methods: A retrospective multicenter study of PA patients in follow-up at 27 Spanish tertiary hospitals (SPAIN-ALDO Register).
Results: Overall, 646 patients with PA were included. At diagnosis, 21.2% (n = 137) had DM and 67% of them had HbA1c levels < 7%. In multivariate analysis, family history of DM (OR 4.00 [1.68-9.53]), the coexistence of dyslipidemia (OR 3.57 [1.51-8.43]) and advanced age (OR 1.04 per year of increase [1.00-1.09]) were identified as independent predictive factors of DM. Diabetic patients were on beta blockers (46.7% (n = 64) vs. 27.5% (n = 140), P < 0.001) and diuretics (51.1% (n = 70) vs. 33.2% (n = 169), p < 0.001) more frequently than non-diabetics. After a median follow-up of 22 months [IQR 7.5-63.0], 6.9% of patients developed DM, with no difference between those undergoing adrenalectomy and those treated medically (HR 1.07 [0.49-2.36], p = 0.866). There was also no significant difference in the evolution of glycemic control between DM patients who underwent surgery and those medically treated (p > 0.05).
Conclusion: DM affects about one quarter of patients with PA and the risk factors for its development are common to those of the general population. Medical and surgical treatment provides similar benefit in glycemic control in patients with PA and DM.
(© 2023. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).)
Databáze: MEDLINE
Externí odkaz: